US FDA's Biologics Center Director Expects It Soon Will See 'Growth Spurt'
Executive Summary
With cell and gene therapies becoming more popular, CBER Director Marks says in an interview with the Pink Sheet that more staff may be needed soon.
You may also be interested in...
BIO 2019 Notebook: Sharpless On Pricing, Marks On Gene Therapy, Takeda On M&A
News and views from day two of the BIO International Convention: US FDA's Sharpless decries the focus on the price of "medical miracle" Zolgensma; CBER Director Marks talks about how his division will staff up to review cell and gene therapy candidates; and Takeda explains why its business development philosophy leads to the valuation seen in the Ariad buyout.
BIO 2019 Notebook: Sharpless On Pricing, Takeda M&A Strategy, FDA Cell And Gene Therapy Staffing
News and views from day two of the BIO International Convention: US FDA's Sharpless decries the focus on the price of "medical miracle" Zolgensma; Takeda explains why its business development philosophy leads to the valuation seen in the Ariad buyout; and CBER Director Marks talks about how his division will staff up to review cell and gene therapy candidates.
Acting FDA Chief Sharpless Pledges 'Full Speed Ahead' On Current Agenda
In his first speech to agency staff, Acting Commissioner Norman Sharpless says FDA will continue working on issues including food safety and nutrition drug, and he is not approaching the post like a temporary caretaker. Sharpless said his appointment does not reflect attempt by President Trump or HHS Secretary Alex Azar to force FDA to change direction set by Scott Gottlieb.